Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 4 Participant assessments

From: Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations

  

3 months pre-PrIMO launch

Launch

3 months post-launch

6 months post-launch

9 months post-launch

12 months post-launch

Site staff participants

 The applied mental health research dissemination and implementation (AMHR) measure

Participant perceptions of model adoption, acceptability, appropriateness, feasibility, reach/access, organizational climate, leadership in implementing, and general leadership skills of the clinic

 Modified clinical sustainability assessment tool (CSAT)

Participant perceptions of the model’s clinical sustainability

 

 The medical conditions regard scale (MCRS)

Biases, emotions, and expectations of chronic medical conditions, including Type2 diabetes, depressive disorder, HIV/AIDS, alcohol use disorder, stimulant use disorder, and opioid use disorder

 Beliefs on MOUD

Prescriber perceptions of and barriers to utilizing MOUD (specifically buprenorphine, methadone, and naltrexone)

 Implementation citizenship behavior scale (ICBS)

Identifies critical behaviors employees exhibit exceeding their expected role to support evidence-based practice implementation

 

b

b

b

b

b

 Change rulers

Readiness and preparedness to implement PrIMO

 Qualitative interviewsa

Experiences providing care for patients with OUD, including use and knowledge (or lack) of the PrIMO model

 

 

Patient participants

  

Baseline (2 weeks post-exposure)

3 months post-baseline

6 months post-baseline

 Consumer AMHR

Participant perceived acceptability of model adoption, acceptability, appropriateness, feasibility, and reach/access

 Substance use stigma mechanism scale (SU-SMS)

Self-reported feelings of internalized stigma

 Qualitative interviewsa

Experiences receiving care for OUD, including knowledge of the PrIMO model and experiences within the clinic

  1. aFor a subset of enrolled participants
  2. bThe champion provider and pharmacist will complete this measure rating other providers, team members, and pharmacy staff